MannKind Corporation Showcases Growth Potential at Healthcare Conference
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy MNKD?
Source: Yahoo Finance
- Strategic Partnership: MannKind's partnership with United Therapeutics (UT) has been confirmed, with CEO Castagna noting that MannKind will be the primary supplier for Tyvaso DPI, indicating a significantly higher revenue floor than initially modeled, which is expected to drive future revenue growth for the company.
- New Product Development: MannKind is collaborating with UT on a second undisclosed compound, and if this product receives FDA approval, MannKind will earn a 10% royalty, providing an additional revenue stream for the company's future.
- Acquisition Integration: MannKind completed its $360 million acquisition of scPharmaceuticals in 2025, integrating FUROSCIX into its product line, with a revenue target of $110-$120 million for 2026, further expanding the company's cardiometabolic business unit.
- Market Outlook: Although analysts previously modeled peak sales for FUROSCIX at $500 million, Castagna indicated that this figure is merely a starting point, highlighting MannKind's growth potential in the treatment of heart and lung diseases, which enhances investor confidence in its future performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MNKD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MNKD
Wall Street analysts forecast MNKD stock price to rise
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 2.370
Low
7.50
Averages
9.25
High
11.00
Current: 2.370
Low
7.50
Averages
9.25
High
11.00
About MNKD
MannKind Corporation is a biopharmaceutical company engaged in transforming chronic disease care through patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, it develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. Its commercial assets include Afrezza, FUROSCIX and V-Go along with Tyvaso DPI. Its commercializing Afrezza (insulin human) Inhalation Powder, an ultra-rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease product, Tyvaso DPI (treprostinil) inhalation powder, is used in the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
MannKind Corporation Showcases Growth Potential at Healthcare Conference
- Strategic Partnership: MannKind's partnership with United Therapeutics (UT) has been confirmed, with CEO Castagna noting that MannKind will be the primary supplier for Tyvaso DPI, indicating a significantly higher revenue floor than initially modeled, which is expected to drive future revenue growth for the company.
- New Product Development: MannKind is collaborating with UT on a second undisclosed compound, and if this product receives FDA approval, MannKind will earn a 10% royalty, providing an additional revenue stream for the company's future.
- Acquisition Integration: MannKind completed its $360 million acquisition of scPharmaceuticals in 2025, integrating FUROSCIX into its product line, with a revenue target of $110-$120 million for 2026, further expanding the company's cardiometabolic business unit.
- Market Outlook: Although analysts previously modeled peak sales for FUROSCIX at $500 million, Castagna indicated that this figure is merely a starting point, highlighting MannKind's growth potential in the treatment of heart and lung diseases, which enhances investor confidence in its future performance.
See More
Avaí Bio Initiates Production of α-Klotho Cells
- Production Milestone: Avaí Bio has initiated the manufacturing of a Master Cell Bank for α-Klotho protein in collaboration with Austrianova, marking a significant transition from laboratory theory to production reality, which is expected to enhance the market potential for anti-aging therapies.
- Broad Market Outlook: The global cell therapy market surpassed $8.2 billion in 2026 and is projected to exceed $45 billion by 2035, positioning Avaí Bio's technology to capture a significant share in this rapidly growing sector.
- Technological Innovation: The Cell-in-a-Box® technology protects transplanted cells from immune system attacks, allowing them to continuously produce α-Klotho, addressing a critical challenge in cell therapy and enhancing treatment efficacy and safety.
- Dual-Program Strategy: Avaí Bio is advancing both the Klothonova anti-aging platform and the Insulinova diabetes program, targeting enormous markets such as Alzheimer's disease, cardiovascular diseases, and kidney disease, demonstrating its strategic positioning in the biotechnology field.
See More
Avaí Bio Initiates α-Klotho Cell Production
- Manufacturing Milestone: Avaí Bio has initiated the production of a Master Cell Bank for α-Klotho protein in collaboration with Austrianova, marking a significant transition from laboratory theory to production reality, which is expected to accelerate the commercialization of anti-aging therapies.
- Massive Market Potential: The global cell therapy market surpassed $8.2 billion in 2026 and is projected to exceed $45 billion by 2035, positioning Avaí Bio's technology to capture a significant share in this rapidly growing sector.
- Technological Advantage: The Cell-in-a-Box® technology protects therapeutic cells from immune system attacks, allowing them to continuously produce α-Klotho, addressing the low survival rates of transplanted cells and enhancing the sustainability of treatment outcomes.
- Strategic Positioning: Avaí Bio's dual-program approach targets both the Klothonova anti-aging platform and the Insulinova diabetes program, with enormous addressable markets, as the Alzheimer's disease market alone is projected to reach $32.8 billion by 2033.
See More
MannKind CEO Buys Shares, Sempra Director Purchases Stock
- MannKind CEO Purchase: CEO Michael Castagna bought 100,000 shares of MNKD at $2.59 each on Tuesday, totaling $259,000, marking his first stock purchase in the past year, indicating confidence in the company's future prospects.
- Price Fluctuation: Castagna's purchase saw an approximate 11% increase at the peak of the trading session, with MNKD reaching $2.88, despite a 1.1% decline on Thursday, suggesting a positive market reaction to his insider buying.
- Sempra Director Buy: On Wednesday, Director Richard J. Mark purchased 2,692 shares of SRE at $93.30 each, totaling $251,164, reflecting an optimistic outlook from company insiders regarding Sempra's future performance.
- Market Performance Analysis: Sempra's stock rose about 0.8% on Thursday, indicating a positive market response to insider buying, which may bolster investor confidence in the company's long-term value.
See More
MannKind CEO Acquires 100,000 Shares
- Executive Purchase: MannKind CEO Michael Castagna purchased 100,000 shares on March 10, 2026, at $2.59 per share, increasing his direct ownership to 2.58 million shares, indicating strong confidence in the company's future.
- Stock Price Surge: Following the announcement of Castagna's purchase, MannKind's stock rose by 7.7%, reflecting a positive market reaction to insider buying, which may bolster investor confidence in the company's outlook.
- Future Revenue Outlook: MannKind projects a revenue run rate of $450 million for 2026 while preparing for the pediatric launch of Afrezza, highlighting several key product catalysts that suggest significant growth potential in the market.
- Earnings Report Impact: Despite missing expectations in its Q4 2025 earnings report, which led to a 52-week low in stock price, the executive purchase and optimistic revenue forecasts may create new investment opportunities for the company.
See More
MannKind Presents New Data on Afrezza at Diabetes Conference
- Clinical Data Presentation: MannKind will showcase clinical and real-world data on Afrezza at the 2026 Advanced Technologies & Treatments for Diabetes Conference, including inhaled insulin use in children and adolescents, which is expected to enhance understanding of post-prandial glucose management and strengthen its market position in diabetes treatment.
- FDA Review Progress: The FDA accepted a supplemental Biologics License Application for Afrezza in children and adolescents aged 4-17 in October 2025, with a target action date of May 29, 2026; if approved, it would be the first needle-free insulin option in over 100 years, potentially transforming pediatric diabetes management.
- Research Findings Sharing: The conference will feature two oral presentations comparing the efficacy of Afrezza across various clinical studies and highlighting data from the INHALE-1 study, focusing on dosing and titration patterns of inhaled insulin in youth, which could lead to improved clinical practices.
- Industry Engagement Opportunity: MannKind executives noted that the ATTD conference serves as a key platform for advancing clinicians' perspectives on meal-time insulin use, and engaging with the global diabetes community will help elevate Afrezza's market awareness and acceptance.
See More
MannKind Corporation Showcases Growth Potential at Healthcare Conference
- Strategic Partnership: MannKind's partnership with United Therapeutics (UT) has been confirmed, with CEO Castagna noting that MannKind will be the primary supplier for Tyvaso DPI, indicating a significantly higher revenue floor than initially modeled, which is expected to drive future revenue growth for the company.
- New Product Development: MannKind is collaborating with UT on a second undisclosed compound, and if this product receives FDA approval, MannKind will earn a 10% royalty, providing an additional revenue stream for the company's future.
- Acquisition Integration: MannKind completed its $360 million acquisition of scPharmaceuticals in 2025, integrating FUROSCIX into its product line, with a revenue target of $110-$120 million for 2026, further expanding the company's cardiometabolic business unit.
- Market Outlook: Although analysts previously modeled peak sales for FUROSCIX at $500 million, Castagna indicated that this figure is merely a starting point, highlighting MannKind's growth potential in the treatment of heart and lung diseases, which enhances investor confidence in its future performance.
See More
Avaí Bio Initiates Production of α-Klotho Cells
- Production Milestone: Avaí Bio has initiated the manufacturing of a Master Cell Bank for α-Klotho protein in collaboration with Austrianova, marking a significant transition from laboratory theory to production reality, which is expected to enhance the market potential for anti-aging therapies.
- Broad Market Outlook: The global cell therapy market surpassed $8.2 billion in 2026 and is projected to exceed $45 billion by 2035, positioning Avaí Bio's technology to capture a significant share in this rapidly growing sector.
- Technological Innovation: The Cell-in-a-Box® technology protects transplanted cells from immune system attacks, allowing them to continuously produce α-Klotho, addressing a critical challenge in cell therapy and enhancing treatment efficacy and safety.
- Dual-Program Strategy: Avaí Bio is advancing both the Klothonova anti-aging platform and the Insulinova diabetes program, targeting enormous markets such as Alzheimer's disease, cardiovascular diseases, and kidney disease, demonstrating its strategic positioning in the biotechnology field.
See More
Avaí Bio Initiates α-Klotho Cell Production
- Manufacturing Milestone: Avaí Bio has initiated the production of a Master Cell Bank for α-Klotho protein in collaboration with Austrianova, marking a significant transition from laboratory theory to production reality, which is expected to accelerate the commercialization of anti-aging therapies.
- Massive Market Potential: The global cell therapy market surpassed $8.2 billion in 2026 and is projected to exceed $45 billion by 2035, positioning Avaí Bio's technology to capture a significant share in this rapidly growing sector.
- Technological Advantage: The Cell-in-a-Box® technology protects therapeutic cells from immune system attacks, allowing them to continuously produce α-Klotho, addressing the low survival rates of transplanted cells and enhancing the sustainability of treatment outcomes.
- Strategic Positioning: Avaí Bio's dual-program approach targets both the Klothonova anti-aging platform and the Insulinova diabetes program, with enormous addressable markets, as the Alzheimer's disease market alone is projected to reach $32.8 billion by 2033.
See More
MannKind CEO Buys Shares, Sempra Director Purchases Stock
- MannKind CEO Purchase: CEO Michael Castagna bought 100,000 shares of MNKD at $2.59 each on Tuesday, totaling $259,000, marking his first stock purchase in the past year, indicating confidence in the company's future prospects.
- Price Fluctuation: Castagna's purchase saw an approximate 11% increase at the peak of the trading session, with MNKD reaching $2.88, despite a 1.1% decline on Thursday, suggesting a positive market reaction to his insider buying.
- Sempra Director Buy: On Wednesday, Director Richard J. Mark purchased 2,692 shares of SRE at $93.30 each, totaling $251,164, reflecting an optimistic outlook from company insiders regarding Sempra's future performance.
- Market Performance Analysis: Sempra's stock rose about 0.8% on Thursday, indicating a positive market response to insider buying, which may bolster investor confidence in the company's long-term value.
See More
MannKind CEO Acquires 100,000 Shares
- Executive Purchase: MannKind CEO Michael Castagna purchased 100,000 shares on March 10, 2026, at $2.59 per share, increasing his direct ownership to 2.58 million shares, indicating strong confidence in the company's future.
- Stock Price Surge: Following the announcement of Castagna's purchase, MannKind's stock rose by 7.7%, reflecting a positive market reaction to insider buying, which may bolster investor confidence in the company's outlook.
- Future Revenue Outlook: MannKind projects a revenue run rate of $450 million for 2026 while preparing for the pediatric launch of Afrezza, highlighting several key product catalysts that suggest significant growth potential in the market.
- Earnings Report Impact: Despite missing expectations in its Q4 2025 earnings report, which led to a 52-week low in stock price, the executive purchase and optimistic revenue forecasts may create new investment opportunities for the company.
See More
MannKind Presents New Data on Afrezza at Diabetes Conference
- Clinical Data Presentation: MannKind will showcase clinical and real-world data on Afrezza at the 2026 Advanced Technologies & Treatments for Diabetes Conference, including inhaled insulin use in children and adolescents, which is expected to enhance understanding of post-prandial glucose management and strengthen its market position in diabetes treatment.
- FDA Review Progress: The FDA accepted a supplemental Biologics License Application for Afrezza in children and adolescents aged 4-17 in October 2025, with a target action date of May 29, 2026; if approved, it would be the first needle-free insulin option in over 100 years, potentially transforming pediatric diabetes management.
- Research Findings Sharing: The conference will feature two oral presentations comparing the efficacy of Afrezza across various clinical studies and highlighting data from the INHALE-1 study, focusing on dosing and titration patterns of inhaled insulin in youth, which could lead to improved clinical practices.
- Industry Engagement Opportunity: MannKind executives noted that the ATTD conference serves as a key platform for advancing clinicians' perspectives on meal-time insulin use, and engaging with the global diabetes community will help elevate Afrezza's market awareness and acceptance.
See More
